[1] Wang LX, Zhang H, Ruan YZ, Chin DP, Xia YY, Cheng SM, et al. Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet 2014;383(9934):2057 − 64. http://dx.doi.org/10.1016/S0140-6736(13)62639-2).CrossRef
[2] Zhang H, Huang F, Chen W, Du X, Zhou MG, Hu J, et al. Estimates of tuberculosis mortality rates in China using the disease surveillance point system, 2004-2010. Biomed Environ Sci 2012;25(4):483 − 8. http://dx.doi.org/10.3967/0895-3988.2012.04.015CrossRef
[3] World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/handle/10665/336069?search-result=true&query=Global+tuberculosis+report+2020&scope=&rpp=10&sort_by=score&order=desc. [2021-3-3].https://apps.who.int/iris/handle/10665/336069?search-result=true&query=Global+tuberculosis+report+2020&scope=&rpp=10&sort_by=score&order=desc.
[4] WHO. WHO TB burden estimates. https://www.who.int/teams/global-tuberculosis-programme/data. [2021-3-3].https://www.who.int/teams/global-tuberculosis-programme/data
[5] Wang LD, Liu JJ, Chin DP. Progress in tuberculosis control and the evolving public-health system in China. Lancet 2007;369(9562):691 − 6. http://dx.doi.org/10.1016/S0140-6736(07)60316-XCrossRef
[6] Zhao YL, Xu SF, Wang LX, Chin DP, Wang SF, Jiang GD, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012;366:2161 − 70. http://dx.doi.org/10.1056/NEJMoa1108789CrossRef
[7] Lin HH, Wang LX, Zhang H, Ruan YZ, Chin DP, Dye C. Tuberculosis control in China: use of modelling to develop targets and policies. Bull World Health Organ 2015;93(11):790 − 8. http://dx.doi.org/10.2471/BLT.15.154492CrossRef
[8] Li RZ, Ruan YZ, Sun Q, Wang XX, Chen MT, Zhang H, et al. Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study. Lancet Glob Health 2015;3(4):e217 − 28. http://dx.doi.org/10.1016/S2214-109X(15)70021-5CrossRef
[9] Gao L, Lu W, Bai LQ, Wang XH, Xu JS, Catanzaro A, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis 2015;15(3):310 − 9. http://dx.doi.org/10.1016/S1473-3099(14)71085-0CrossRef
[10] Huynh GH, Klein DJ, Chin DP, Wagner BG, Eckhoff PA, Liu RZ, et al. Tuberculosis control strategies to reach the 2035 global targets in China: the role of changing demographics and reactivation disease. BMC Med 2015;13:88. http://dx.doi.org/10.1186/s12916-015-0341-4CrossRef
[11] Lung T, Marks GB, Nhung NV, Anh NT, Le Phuong Hoa N, Anh LTN, et al. Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. Lancet Glob Health 2019;7(3):e376 − 84. http://dx.doi.org/10.1016/S2214-109X(18)30520-5CrossRef
[12] World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018. License: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/handle/10665/260233. [2021-3-3].https://apps.who.int/iris/handle/10665/260233
[13] Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis 2016;16(11):1269 − 78. http://dx.doi.org/10.1016/S1473-3099(16)30216-XCrossRef
[14] World Health Organization. Rapid Communication: on forthcoming changes to the programmatic management of tuberculosis preventive treatment. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO. https://www.who.int/tb/publications/2020/rapid-communication-on-forthcoming-changes-to-tpt/en/. [2021-3-3].https://www.who.int/tb/publications/2020/rapid-communication-on-forthcoming-changes-to-tpt/en/
[15] Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, et al. Prevention of M. tuberculosis infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med 2018;379(2):138 − 49. http://dx.doi.org/10.1056/NEJMoa1714021CrossRef
[16] Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med 2019;381(25):2429 − 39. http://dx.doi.org/10.1056/NEJMoa1909953CrossRef
[17] Fineberg HV. Pandemic preparedness and response—Lessons from the H1N1 Influenza of 2009. N Engl J Med 2014;370(14):1335 − 42. http://dx.doi.org/10.1056/NEJMra1208802CrossRef
[18] Oppenheim B, Gallivan M, Madhav NK, Brown N, Serhiyenko V, Wolfe ND, et al. Assessing global preparedness for the next pandemic: development and application of an Epidemic Preparedness Index. BMJ Glob Health 2019;4(1):e001157. http://dx.doi.org/10.1136/bmjgh-2018-001157CrossRef